| 產品名稱 | C2C12 |
|---|---|
| 商品貨號 | B164081 |
| Organism | Mus musculus, mouse |
| Tissue | muscle |
| Cell Type | myoblast |
| Product Format | frozen |
| Morphology | myoblast |
| Culture Properties | adherent |
| Biosafety Level | 1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Strain | C3H |
| Applications | transfection host |
| Storage Conditions | liquid nitrogen vapor phase |
| Images |  |
| Derivation | This is a subclone (produced by H. Blau, et al) of the mouse myoblast cell line established by D. Yaffe and O. Saxel. |
| Comments | The C2C12 cell line differentiates rapidly, forming contractile myotubes and producing characteristic muscle proteins. Treatment with bone morphogenic protein 2 (BMP-2) cause a shift in the differentiation pathway from myoblastic to osteoblastic. Tested and found negative for ectromelia virus (mousepox). |
| Complete Growth Medium | The base medium for this cell line is ATCC-formulated Dulbecco's Modified Eagle's Medium, Catalog No. 30-2002. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
|
| Seeding Density | It is important that these cells be seeded at a density of only 5.0 X103 viable cells/cm2; refer to the COA for the batch specific information. |
| Subculturing | Cultures must not be allowed to become confluent as this will deplete the myoblastic population in the culture. Myotube formation is enhanced when the medium is supplemented with 10% horse serum instead of fetal bovine serum.
Medium Renewal: Every two to three days
|
| Cryopreservation | Freeze medium: Complete growth medium supplemented with 5% (v/v) DMSO Storage temperature: liquid nitrogen vapor phase |
| Culture Conditions | Temperature: 37.0°C |
| Name of Depositor | B Paterson |
| References | Qing Y, et al. Inhibitory effects of iron on bone morphogenetic protein 2-induced osteoblastogenesis. J. Bone Miner. Res. 26(6): 1188-1196, 2011. PubMed: 21308772 Chow YH, et al. Improvement of hepatitis B virus DNA vaccines by plasmids coexpressing hepatitis B surface antigen and interleukin-2. J. Virol. 71: 169-178, 1997. PubMed: 8985336 Hsu DK, et al. Identification of a murine TEF-1-related gene expressed after mitogenic stimulation of quiescent fibroblasts and during myogenic differentiation. J. Biol. Chem. 271: 13786-13795, 1996. PubMed: 8662936 Kessler PD, et al. Gene delivery to skeletal muscle results in sustanined expression and systemic delivery of a therapeutic protein. Proc. Natl. Acad. Sci. USA 93: 14082-14087, 1996. PubMed: 8943064 Katagiri T, et al. Bone morphogenetic protein-2 converts the differentiation pathway of C2C12 myoblasts into the osteoblast lineage [published erratum appears in J Cell Biol 1995 Feb;128(4):following 713]. J. Cell Biol. 127: 1755-1766, 1994. PubMed: 7798324 Blau HM, et al. Plasticity of the differentiated state. Science 230: 758-766, 1985. PubMed: 2414846 Yaffe D, Saxel O. Serial passaging and differentiation of myogenic cells isolated from dystrophic mouse muscle. Nature 270: 725-727, 1977. PubMed: 563524 |
| 梅經(jīng)理 | 17280875617 | 1438578920 |
| 胡經(jīng)理 | 13345964880 | 2438244627 |
| 周經(jīng)理 | 17757487661 | 1296385441 |
| 于經(jīng)理 | 18067160830 | 2088210172 |
| 沈經(jīng)理 | 19548299266 | 2662369050 |
| 李經(jīng)理 | 13626845108 | 972239479 |
